A 77-year-old man with heart failure (LVEF 32%), CKD stage 3a (eGFR 52), and type 2 diabetes has been on Ramipril 10 mg, Bisoprolol 10 mg, Furosemide ...

Question

A 77-year-old man with heart failure (LVEF 32%), CKD stage 3a (eGFR 52), and type 2 diabetes has been on Ramipril 10 mg, Bisoprolol 10 mg, Furosemide 80 mg, Spironolactone 25 mg, and Empagliflozin 10 mg. His symptoms remain NYHA class II. According to recent heart failure guidance, should an SGLT2 inhibitor be continued?

Accepted Answer

Yes - SGLT2 inhibitors (Dapagliflozin or Empagliflozin) are now recommended as foundational therapy in HFrEF, providing mortality and hospitalisation benefit independent of diabetes status

Answer

No - Empagliflozin is only for diabetes and not relevant in heart failure

Answer

Only if HbA1c is above 53 mmol/mol

Answer

It should be stopped as it interacts with Spironolactone

Answer

Only if eGFR is above 60

uk-dgm MCQ (SBA): SGLT2 Inhibitors in Heart Failure